Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Company Information
About this company
Key people
David Moatazedi
President, Chief Executive Officer, Director
Tatjana Mitchell
Chief Financial Officer
Rui L. Avelar
Chief Medical Officer, Head - Research and Development
Vikram Malik
Independent Chairman of the Board
David N. Gill
Independent Director
Karah Parschauer
Independent Director
Brady Stewart
Independent Director
Albert G. White
Independent Director
Click to see more
Key facts
- Shares in issue64.82m
- EPICEOLS
- ISINUS30052C1071
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$297.52m
- Employees329
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.